Skip to main content

Table 1 Patient characteristics

From: Left ventricular diastolic dysfunction in pulmonary hypertension predicts functional capacity and clinical worsening: a tissue phase mapping study

Etiology [33] Number (%)
1. PAH 11 (28)
 - 1.1 Idiopathic 10
 - 1.2 Heritable 1
1.4 Associated with (APAH): 21 (53)
 - 1.4.1 CTD 20
  - Limited cutaneous systemic sclerosis 13
  - Diffuse cutaneous systemic sclerosis 2
  - Systemic lupus erythematosus 3
  - Sjögren’s syndrome 1
  - Mixed CTD 1
 - 1.4.3 Portal Hypertension 1
4 CTEPH 8 (20)
 - Proximal (operable) 5
 - Distal (inoperable) 3
Right Heart Catheterization (RHC) data (n = 29)
 Time interval between CMR and RHC (days) 8 (IQR 12)
 Mean pulmonary artery pressure (mPAP, mmHg) 46 ± 13
 Pulmonary vascular resistance (PVR, dyn · s/cm5) 523 (IQR 402–717)
World Health Organization class (%)
 I 1 (2.5)
 II 14 (35)
 III 22 (55)
 IV 3 (7.5)
6-MWD (metres) 372 (IQR 286–450)
Vasodilator therapy
 Phosphodiesterase type 5 inhibitor 28 (70)
 Endothelin receptor antagonist 22 (55)
 Intravenous prostacyclin 1 (3)
 Treatment naive 8 (20)
 Oral monotherapy 14 (35)
 Dual combination oral therapy 16 (40)
 Triple combination therapy 1 (3)
Additional PH therapies
 Oral prostacyclin 1 (3)
 Inhaled prostacyclin 1 (3)
 Tyrosine-kinase inhibitor 2 (5)